JAMA : the journal of the American Medical Association
-
There are limited efficacious treatments for Alzheimer disease. ⋯ Among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab significantly slowed clinical progression at 76 weeks in those with low/medium tau and in the combined low/medium and high tau pathology population.